Emerging biological insights and novel treatment strategies in multiple myeloma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Opinion on Emerging Drugs

• Publication date

  2012-08-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/14728214.2012.713345PMID 22920042
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lenalidomide after stem-cell transplantation for multiple myeloma.

  2012cited by this paper
• A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

  2012cited by this paper
• BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STAUDY.

  2012cited by this paper
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  2012cited by this paper
• Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

  2012cited by this paper
• Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

  2012cited by this paper
• A phase 1 , multicenter , open-label , dose escalation study of elotuzumab in patients with advanced multiple myeloma

  2012cited by this paper
• Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia

  2012cited by this paper
• Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding

  2012influential reference
• Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study.

  2012cited by this paper
• Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM).

  2012cited by this paper
• Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

  2012cited by this paper
• Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study.

  2012cited by this paper
• Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study

  2012cited by this paper
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  2012cited by this paper
• Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

  2012influential reference
• PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.

  2012cited by this paper
• Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients

  2012cited by this paper
• Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

  2012cited by this paper
• A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide, and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma.

  2012cited by this paper
• Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol.

  2012cited by this paper
• An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

  2012cited by this paper
• Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

  2012cited by this paper
• ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).

  2012cited by this paper
• A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

  2012cited by this paper
• Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

  2012cited by this paper
• Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

  2012cited by this paper
• Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

  2012influential reference
• High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02

  2011cited by this paper
• Lenalidomide in the treatment of chronic lymphocytic leukemia

  2011cited by this paper
• Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma.

  2011cited by this paper
• Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysis

  2011cited by this paper
• Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

  2011cited by this paper
• A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,

  2011cited by this paper
• Multiple myeloma.

  2011cited by this paper
• Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations

  2011cited by this paper
• Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial

  2011cited by this paper
• The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

  2011cited by this paper
• Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma,

  2011cited by this paper
• Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHA-DEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients With Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN

  2011cited by this paper
• Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)

  2011cited by this paper
• Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

  2011cited by this paper
• Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study

  2011cited by this paper
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• Treating chronic lymphocytic leukemia with thalidomide and lenalidomide

  2011cited by this paper
• Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

  2011cited by this paper
• Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment

  2011cited by this paper
• Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

  2011cited by this paper
• Advances in imaging and the management of myeloma bone disease.

  2011cited by this paper
• Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.

  2011cited by this paper
• Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

  2011cited by this paper
• Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

  2011cited by this paper
• Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis

  2011cited by this paper
• Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

  2011cited by this paper
• Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

  2011cited by this paper
• The Growth Factor Independence 1 variant form GFI136N Predisposes to Acute Myeloid Leukemia by Inducing Epigenetic Changes in Oncogenes Such As Hoxa9

  2011cited by this paper
• HSP90 inhibitors as therapy for multiple myeloma.

  2011cited by this paper
• Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial

  2011cited by this paper
• Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

  2011cited by this paper
• In Vivo Blockade of Individual Notch Ligands and Receptors Provides a New Targeted Therapeutic Approach In Graft-Versus-Host Disease

  2011cited by this paper
• PR‐924, a selective inhibitor of the immunoproteasome subunit LMP‐7, blocks multiple myeloma cell growth both in vitro and in vivo

  2011cited by this paper
• Identification of a Primary Target of Thalidomide Teratogenicity

  2010influential reference
• Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

  2010cited by this paper
• Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs

  2010cited by this paper
• AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

  2010cited by this paper
• Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

  2010cited by this paper
• Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma

  2010cited by this paper
• Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

  2010cited by this paper
• Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

  2010cited by this paper
• Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM)

  2010cited by this paper
• Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

  2010cited by this paper
• MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenström's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors

  2010influential reference
• Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

  2010cited by this paper
• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

  2010cited by this paper
• Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.

  2010cited by this paper
• Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

  2010cited by this paper
• Phase II study of bortezomib, thalidomide, and dexamethasone /-cyclophosphamide as induction therapy in previously untreatedmultiple myeloma (MM): safety and activity including evaluationof MRD

  2010cited by this paper
• Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.

  2010cited by this paper
• Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

  2010cited by this paper
• Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study

  2010cited by this paper
• Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.

  2010cited by this paper
• Survival and years of life lost in different age cohorts of patients with multiple myeloma.

  2010cited by this paper
• First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

  2010cited by this paper
• Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.

  2010cited by this paper
• Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

  2010cited by this paper
• HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

  2010cited by this paper
• Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

  2010cited by this paper
• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.

  2010cited by this paper
• Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

  2010cited by this paper
• Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

  2010cited by this paper
• Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

  2010cited by this paper
• Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

  2010cited by this paper
• Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

  2010influential reference
• Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

  2010cited by this paper
• Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

  2010cited by this paper
• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

  2010cited by this paper
• A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

  2010cited by this paper
• Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

  2010cited by this paper

• New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma

  2025cites this paper
• METHOD DEVELOPMENT AND VALIDATION OF IXAZOMIB DRUG BY RP-HPLC IN BULK AND PHARMACEUTICAL DOSAGE FORM

  2021cites this paper
• OTT_A_237343 401..411

  2020cites this paper
• PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2

  2020cites this paper
• In vitro comparison of the cytotoxic effects of statins on U266 myeloma cell line

  2019cites this paper
• Opposing SMAD-6 and SMAD-7 Expression Profiles Correlate with the Sensitivity of Multiple Myeloma Cells to Bone Morphogenetic Protein (BMP)-2

  2018cites this paper
• Multiples Myelom – aktuelle Standards in Diagnostik und Therapie

  2017cites this paper
• The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials

  2016cites this paper
• Spotlight on ixazomib: potential in the treatment of multiple myeloma

  2016cites this paper
• Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting

  2016cites this paper
• The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM

  2015cites this paper
• Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells

  2015cites this paper
• Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

  2014cites this paper
• The emerging role of carfilzomib combination therapy in the management of multiple myeloma

  2014cites this paper
• A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events

  2014cites this paper
• Epigenetic gene regulation in multiple myeloma and mood disorders

  2013cites this paper